Literature DB >> 11416734

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

L Ruiz1, G Carcelain, J Martínez-Picado, S Frost, S Marfil, R Paredes, J Romeu, E Ferrer, K Morales-Lopetegi, B Autran, B Clotet.   

Abstract

OBJECTIVE: To evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection. PATIENTS AND
DESIGN: Subjects with at least 2 years virus suppression during antiretroviral therapy and a CD4 : CD8 ratio > 1 were randomly assigned to interrupt highly active antiretroviral treatment (HAART) three times (n = 12) or to continue their previous HAART (n = 14).
RESULTS: In 10/12 interrupter patients a rebound of HIV-1 RNA was detected in all three structured treatment interruptions (STI). Plasma virus doubling time was shorter during the first STI than in the second and third STI, corresponding to an average 13% reduction in viral basic reproductive rate. However, the mean time before plasma viral load rose to > 50 copies/ml was significantly shorter in the second and third STI. The average frequency of HIV-specific CD8 T cells in the interrupter patients at the end of the third STI cycle was significantly higher compared with the baseline and the end of the first STI. A substantial increase in HIV-specific CD8 T cell frequencies was found in four interrupter patients, whereas there were no changes in all 14 non-interrupter individuals. A weak p24-specific T helper response developed in 5/12 interrupter patients compared with no response in non-interruptors, but these responses were transient and disappeared rapidly.
CONCLUSION: The increase in the control of viral replication, and positive effects of STI on immune responses in this population should encourage the further development of HIV-specific immune-based therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11416734     DOI: 10.1097/00002030-200106150-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  41 in total

1.  Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?

Authors:  Diane V Havlir
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 3.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 4.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

5.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

6.  Controlling the Evolution of Resistance.

Authors:  Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski
Journal:  J Process Control       Date:  2011-03-01       Impact factor: 3.666

7.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.

Authors:  Xu G Yu; Marylyn M Addo; Eric S Rosenberg; William R Rodriguez; Paul K Lee; Cecily A Fitzpatrick; Mary N Johnston; Daryld Strick; Philip J R Goulder; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.

Authors:  Gideon Goldstein; Eve Damiano; Mardik Donikyan; Malika Pasha; Erik Beckwith; John Chicca
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

10.  Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.

Authors:  Julia G Prado; Ayumi Shintani; Margarita Bofill; Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.